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A FRACTION OF COMMERCIAL YEAST WHICH PROTECTS
AGAINST BACTERIAL INFECTION
A Preliminary Note
Since 1940 when we began a study of sensitization in laboratory animals
treated with pertussis vaccine we have emphasized the role of the bacterial
protein in this phenomenon. Considerable information has been accumu-
lated which indicates that vaccination with Hemnophilus pertussis, while
increasing resistance against infection by the same organism will, at the
same time, produce hypersensitivity to the Hen?ophilus pertussis antigen.
Such sensitivity, however, is not specific for pertussis but crosses with
several other species of gram negative bacteria.1 28 Furthermore, mice
immunized against pertussis are much more susceptible to infection by
other gram negative bacteria than are their normal litter mates. Apparently,
specific immunization can produce a non-specific lowering of resistance
which predisposes the host to unrelated infections"5 and this may well be
listed as another untoward effect of bacterial allergy.
Because bacterial protein has been shown to play a part in hypersensitiv-
ity and, from the above observation, is implicated in the etiology of infec-
tions, the search for an appropriate protein for desensitization was under-
taken. The obvious selection was protein associated with the nucleic acid
of the bacterial cell from the specific Henmophilus organism. Injection of
this material reinforced the resistance of sensitized animals. However, since
hypersensitivity is not species specific, the possibility of another source of
comparable material was apparent and it was found that a commercial
preparation of yeast sodium nucleate would not only reduce the hypersensi-
tivity of vaccinated animals to the same pertussis antigen, but would make
them refractory to gram negative bacteria. This logically lead to the possi-
bility of protection for normal animals against similar infection.
Our numerous experiments prove that normal mice after injection with
sodium nucleate are protected against infection by Proteus, Pasteurella,
Brucella and E. coli organisms. Subsequent studies indicated that different
brands of sodium nucleate were variable in potency; some were even inac-
tive. Furthermore, the protective dosage of the active preparations ran as
high as 100 mg./mouse. In search of the active principle we looked to the
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source material and undertook the fractionation of yeast. Although we did
not identify the principle agent, we have succeeded in isolating a very
potent fraction from a pressed cake of baker's yeast. Since the therapy of
gram negative infections presents a persistent clinical problem, we have
hastened to present these data in preliminary form. Details of the prepara-
tion and identification of the active material will be described later.
Briefly, it can be said that from 4 lbs. of yeast cake, 1.5 gm. of a dry
material has been isolated which represents that particular yeast fraction
TABLE 1: SURVIVAL OF NORMAL AND SENSITIZED MICE* WVITH 100 MG. SODIUM NUCLEATE
(Sensitized mice treated with H. pertussis vaccine.)
Organism
Proteus vzulgaris
OX19
Pasteurella
multocida
Brucella suis
Dose
1.5 billion cells/mouset
Normal mice Sensitized mnice
Control- Protected- Control- Protected-
no treatment NaNucleate no treatment Na nucleate
Sur- Sur- Sur- Sur-
tivors % vivors % vivors % vivors %
2/40 5% 45/57 78% 4/30 13% 49/65 75%
100 organisms/mouse 6/18 33% 26/41 93% 7/38 18% 9/20 45%
2-4 billion organisms/ 2/20 10% 16/20 80%
mouse
* In every experiment mice were of the same age, sex and strain.
t This dose constitutes 1 LD for normal mice but 5 LD for sensitized mice.
containing protein and associated with biologic activity. Injection of as
little as 0.3 mg. per mouse and 7.5 mg. per guinea pig protects these ani-
mals against a lethal dose of live Proteus. To contrast the enhanced pro-
tection provided by the yeast fraction with the protection afforded by active
preparations of sodium nucleate we have grouped our data so that Table 1
shows the effect of 100 mg. of sodium nucleate against infection by one of
three different organisms, and Table 2 shows the comparable protection
provided by the yeast fraction in Proteus infections of both mice and
guinea pigs.
From these data it is evident that commercial sodium nucleate in large
doses and a new yeast preparation in small doses will protect animals
against infection with gram negative bacteria. As far as we know yeast is
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not currently used in the preparation of antibiotics although seven years
ago Sartory and Meyer' reported the in vitro inhibition of Proteus by yeast
macerate. In our experiments we could not confirm these observations.
Moreover, we have found that sodium nucleate has no in vitro bacteriocidal
or bacteriostatic activity whatever.
TABLE 2: PROTECTION BY THE NEWr YEAST PRODUCT AGAINST Proteus OX19
INFECTION IN MICE AND GUINEA PIGS
Protected-
Test Dosage-Live Proteus Conttrol- newyeast
animal organismts no treatment product*
Survivors % Survivors %o
Guinea pig 25 billion 2/5 40%o 5/5 100/cl
Guinea pig 50 billion 1/6 17% 7/8 88%o
Mouse 2.5 billion 0/6 0% 15/18 83%
* 7.5 mg./guinea pig; 0.3 mg./mouse.
SUMMARY
Normal and sensitized mice are protected against the various gram nega-
tive bacteria tested by certain commercial preparations of sodium nucleate.
In a search for a active component we have isolated from a pressed cake of
baker's yeast a potent fraction which is over 300-fold more effective.
Further work concerning the purification and identification of this yeast
fraction is in progress.
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